Jiahai Shi

Carcell Biopharma, Inc. is a Singaporean pre-clinical biotech company that operates on a "hub-and-spoke" model, with two platforms that develop next-generation cell and gene therapies. Carcell closed its oversubscribed seed round of US$ 16.6 million in 2021, led by Hyfinity Investments. The company's vision is to house a "platform of platforms" model, accelerating the development and translation of next-generation cell and gene therapies. Recently, Carcell welcomed two new advisors, Prof. Jianzhu Chen of MIT, and Dr. Hagop Youssoufian, to its scientific and clinical advisory boards, respectively. The company was founded in 2021 by a team of serial entrepreneurs and seasoned biopharma executives, including XQ Lin, the chairman and founder of EVX Ventures, Prof. Jiahai Shi, an assistant professor at the National University of Singapore, and Dr. Lanlin Wu, the former CEO of Dendreon.

Carmine Therapeutics Pte Ltd. develops and manufactures medicines based on red blood cell extracellular vesicles. The company was founded by Harvey Lodish, Minh Le, XiangQian Lin and Jiahai Shi in 2019 and is headquartered in Singapore.